beta

EVLO

Evelo Biosciences Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

evelo biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. these new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. by finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, evelo can improve the speed, cost and success of drug discovery and development. evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. evelo biosciences was conceived and created within venturelabs®, flag

Market Cap: 7 Million

Primary Exchange: NASDAQ

Website: evelobio.com

Shares Outstanding: 18.9 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.9268449519539241

Sector: Professional, Scientific, and Technical Services

Industry: Research and Development in Biotechnology

Ethical Flags

Longest drawdown: 956 trading days

From: 2021-01-28 To: 2023-12-11

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud